SuperGen Reports 2008 Second Quarter Financi...(ion in vitro. SGI-1776 induced...)

in vitro. SGI-1776 induced significant tumor regression in MV-4-11

(AML) and MOLM-13 (AML) xenograft models.

-- MP-470, an early clinical-stage multi-targeted tyrosine kinase

inhibitor and Rad51 suppressor, was shown to be bioavailable and

well-tolerated in a first in human study (Abstract No. 4083). The

presentation entitled, "MP-470, a potent oral Rad51 suppressor is

safe and tolerable in first-in-human study," summarized the data

suggesting that MP-470 is well-tolerated when administered in doses

of up to 900 mg per day. Additionally, it was found that Rad51

expression is modulated in a dose-dependent manner. This is

consistent with pre-clinical studies where MP-470 was shown to

sensitize cancer cells to DNA damaging agents and radiation therapy

by suppressing Rad51, a protein responsible for repair of double

strand DNA breaks in cancer cells.

-- MP-470 was shown to effectively sensitize prostate and breast cancer

cells to erlotinib (Abstract No. 671). The presentation entitled,

"Inhibition of erlotinib resistance on HER-family tyrosine kinases

by combination with MP-470, a multi-targeted TK inhibitor in

prostate and breast cancer," highlighted data suggesting that the

combination of MP-470 and erlotinib inhibits the binding of the p85

subunit of PI3K. The poster outlined the enhanced impact of the

combination of MP-470 and erlotinib, compared to either agent alone

in reducing phosphorylation of Akt, ERK1/2, EGFR/HER1, HER2/Neu, and

HER3.

-- S-110, a DNA methyltransferase inhibitor, demonstrated an improved

in vivo activity profile over decitabine (Abstract No. 2613). The

presentation entitled, "Decitabine administered as a Dinucleotide'/>"/>